Antoine Sakr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antoine Sakr has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Liset Stoletniy
Loma Linda University Medical Center, Loma Linda, CA, USA
6 shared publications - Dmitry Abramov
Division of Cardiovascular Medicine, Loma Linda University Medical Center , Loma Linda, CA
5 shared publications - Dennis Grewal
Loma Linda University Medical Center, Loma Linda, CA, USA
4 shared publications Dante Garcia
3 shared publicationsDmitry Abramov
Cardiology Department, Loma Linda University Medical Center, Loma Linda, California
3 shared publicationsJoshua Coney
Division of Cardiology, Medical University of South Carolina Health, Charleston, South Carolina
3 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1)
The Neurocardiac Axis in Myocardial Infarction: Emerging Role of Brain-Heart Inflammatory Signaling
Myocardial infarctions (MI) can lead to post-MI cardiac and neurocognitive dysfunctions due to the complex interplay of the neurocardiac “brain and heart” axis. Imbalanced autonomic nervous system (ANS) synchronization within the neurocardiac axis leads to infarcted or damaged tissues. This may influence potential inflammatory signaling mechanisms in post-MI pathology and, by extension, the repercussions of acute and chronic MI outcomes. Here, previous in-vivo experimental rodent and porcine models with surgically induced MI/heart failure (HF) and in-vitro models report brain-heart association regions and pathologies. Furthermore, clinical meta-analyses were compiled to provide a broad overview of the varying impacts of post-MI pathologies on the brain and heart. Other supplemental perspectives postulate other relevant inflammatory mechanisms, such as neurohumoral imbalances, a weakened immune system, and genetic predispositions, which expand a more holistic view of post-MI mechanisms. By examining in closer detail the inflammatory cells (e.g., microglia and astrocytes) and the blood-brain barrier (BBB), cardiogenic trauma from MI incites chronic systemic inflammation and exacerbates the stress response. This further weakens the BBB, prolongs neuroinflammation, and damages sites responsible for cardiac regulation and repair. Graphical Abstract Neurocardiac axis dysregulation induced by MI. This general schematic shows how the proper functioning of the neurocardiac axis relies on the undisrupted cardio-regulatory regions in the brain innervating the heart. Disruption to this axis, exacerbated by the onset of MI and prolonged, unresolved inflammation, contributes to cardiac and brain pathological outcomes
- 19 August 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1)
Open AccessThe Neurocardiac Axis in Myocardial Infarction: Emerging Role of Brain-Heart Inflammatory Signaling
Myocardial infarctions (MI) can lead to post-MI cardiac and neurocognitive dysfunctions due to the complex interplay of the neurocardiac “brain and heart” axis. Imbalanced autonomic nervous system (ANS) synchronization within the neurocardiac axis leads to infarcted or damaged tissues. This may influence potential inflammatory signaling mechanisms in post-MI pathology and, by extension, the repercussions of acute and chronic MI outcomes. Here, previous in-vivo experimental rodent and porcine models with surgically induced MI/heart failure (HF) and in-vitro models report brain-heart association regions and pathologies. Furthermore, clinical meta-analyses were compiled to provide a broad overview of the varying impacts of post-MI pathologies on the brain and heart. Other supplemental perspectives postulate other relevant inflammatory mechanisms, such as neurohumoral imbalances, a weakened immune system, and genetic predispositions, which expand a more holistic view of post-MI mechanisms. By examining in closer detail the inflammatory cells (e.g., microglia and astrocytes) and the blood-brain barrier (BBB), cardiogenic trauma from MI incites chronic systemic inflammation and exacerbates the stress response. This further weakens the BBB, prolongs neuroinflammation, and damages sites responsible for cardiac regulation and repair. Graphical Abstract Neurocardiac axis dysregulation induced by MI. This general schematic shows how the proper functioning of the neurocardiac axis relies on the undisrupted cardio-regulatory regions in the brain innervating the heart. Disruption to this axis, exacerbated by the onset of MI and prolonged, unresolved inflammation, contributes to cardiac and brain pathological outcomes
- Open Access
- 3 June 2024
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2024 (6) , rjae430
Calcified amorphous tumor attached to the membranous septum: a rare clinical entity
We report a rare case of a pedunculated calcified amorphous tumor (CAT) of the left ventricle attached by a stalk to the membranous septum in a 74-year-old woman who presented with a cerebrovascular accident. We believe this is the first report of a CAT attached to the membranous septum.
- 3 June 2024
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2024 (6) , rjae430
Open AccessCalcified amorphous tumor attached to the membranous septum: a rare clinical entity
We report a rare case of a pedunculated calcified amorphous tumor (CAT) of the left ventricle attached by a stalk to the membranous septum in a 74-year-old woman who presented with a cerebrovascular accident. We believe this is the first report of a CAT attached to the membranous septum.
- 1 December 2021
- Published by Elsevier in Transplantation Proceedings
- Vol. 53 (10) , 3036-3038
Echocardiography-Based Hemodynamic Monitoring Use on Inpatients Listed for Heart Transplantation Under 2018 Allocation Policy in United States
- 1 December 2021
- Published by Elsevier in Transplantation Proceedings
- Vol. 53 (10) , 3036-3038
Echocardiography-Based Hemodynamic Monitoring Use on Inpatients Listed for Heart Transplantation Under 2018 Allocation Policy in United States
- 1 July 2021
- Published by Elsevier in The American Journal of Cardiology
- Vol. 151
Open AccessContents
- 1 July 2021
- Published by Elsevier in The American Journal of Cardiology
- Vol. 151, 64-69
Role of Guideline Directed Medical Therapy Doses and Optimization in Patients Hospitalized With Decompensated Systolic Heart Failure
- 1 July 2021
- Published by Elsevier in The American Journal of Cardiology
- Vol. 151, 64-69
Role of Guideline Directed Medical Therapy Doses and Optimization in Patients Hospitalized With Decompensated Systolic Heart Failure
- 28 May 2021
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 78 (3) , 336-345
A Review of Inotropes and Inopressors for Effective Utilization in Patients With Acute Decompensated Heart Failure
Inotropes and inopressors are often first-line treatment in patients with cardiogenic shock. We summarize the pharmacology, indications, and contraindications of dobutamine, milrinone, dopamine, norepinephrine, epinephrine, and levosimendan. We also review the data on the use of these medications for acute decompensated heart failure and cardiogenic shock in this article.
- 28 May 2021
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 78 (3) , 336-345
A Review of Inotropes and Inopressors for Effective Utilization in Patients With Acute Decompensated Heart Failure
Inotropes and inopressors are often first-line treatment in patients with cardiogenic shock. We summarize the pharmacology, indications, and contraindications of dobutamine, milrinone, dopamine, norepinephrine, epinephrine, and levosimendan. We also review the data on the use of these medications for acute decompensated heart failure and cardiogenic shock in this article.
- 12 May 2021
- Published by Wiley in Clinical Transplantation
- Vol. 35 (7) , e14345
Impact of heart transplant allocation change on competing waitlist outcomes among listing strategies
In 2018, the United Network for Organ Sharing (UNOS) adopted a 6‐tier system for heart allocation which shifted patterns in listing strategies. The effects of the change on waitlist survival and transplantation rates have yet to be substantiated by analysis of competing outcomes among various listing strategies. This study included all adult patients listed for first‐time heart transplantation in UNOS between 10/17/15 and 6/12/20. Clinical characteristics were compared before and after allocation change among various listing strategies: no support, inotropes, intra‐aortic balloon pump, durable left ventricular assist device (LVAD), temporary VAD, and extracorporeal membrane oxygenation. Fine‐Gray proportional subhazard models were used to estimate the effect of allocation change on competing waitlist outcomes—transplantation, death, or removal from waitlist—among each strategy. During the study period, there were 17 422 patients listed for heart transplantation. Among each listing strategy, clinical characteristics were similar before and after allocation change. Subhazard models demonstrated reduced risk for waitlist mortality (p < .001) among each strategy except temporary VAD and increased transplantation rates (p < .001) among each strategy except for durable LVAD. These results validate the association of the new allocation system on waitlist outcomes across listing strategies.
- 12 May 2021
- Published by Wiley in Clinical Transplantation
- Vol. 35 (7) , e14345
Impact of heart transplant allocation change on competing waitlist outcomes among listing strategies
In 2018, the United Network for Organ Sharing (UNOS) adopted a 6‐tier system for heart allocation which shifted patterns in listing strategies. The effects of the change on waitlist survival and transplantation rates have yet to be substantiated by analysis of competing outcomes among various listing strategies. This study included all adult patients listed for first‐time heart transplantation in UNOS between 10/17/15 and 6/12/20. Clinical characteristics were compared before and after allocation change among various listing strategies: no support, inotropes, intra‐aortic balloon pump, durable left ventricular assist device (LVAD), temporary VAD, and extracorporeal membrane oxygenation. Fine‐Gray proportional subhazard models were used to estimate the effect of allocation change on competing waitlist outcomes—transplantation, death, or removal from waitlist—among each strategy. During the study period, there were 17 422 patients listed for heart transplantation. Among each listing strategy, clinical characteristics were similar before and after allocation change. Subhazard models demonstrated reduced risk for waitlist mortality (p < .001) among each strategy except temporary VAD and increased transplantation rates (p < .001) among each strategy except for durable LVAD. These results validate the association of the new allocation system on waitlist outcomes across listing strategies.
- Open Access
- 1 January 2021
- Published by SAGE Publications in Clinical Medicine Insights: Cardiology
- Vol. 15
Predictors of In-hospital Mortality in Cardiogenic Shock Patients on Vasoactive or Inotropic Support
Though controversial, the short-duration in-patient use of inotropes in cardiogenic shock (CS) remain an ACC/AHA Class IIa indication, and are frequently used in the initial treatment of CS. We evaluated in-patient mortality and effect on mortality risk of commonly used vasoactive inotropic medications for the medical management of SCAI stage B and C cardiogenic shock patients in a tertiary care cardiac care unit: dobutamine, dopamine, milrinone, and norepinephrine. We retrospectively evaluated 342 patients who received dobutamine, milrinone, dopamine, norepinephrine or a combination of these medications for SCAI stage B and C cardiogenic shock. Cox proportional hazards were used to form longitudinal mortality predictions. Overall in-patient mortality was 18%. Each 1 µg/kg/minute increase in dobutamine independently corresponded to a 15% increase in risk of mortality. High dose dobutamine >3 µg/kg/minute is associated with 3-fold increased risk compared to ⩽3 µg/kg/minute (P < .001). Use of milrinone, norepinephrine, and dopamine were not independently associated with mortality. We demonstrate that the overall in-hospital mortality of SCAI stage B and C cardiogenic shock patients medically managed on inotropes was not in excess of prior studies. Dobutamine was independently associated with mortality, while other vasoactive inotropic medications were not. Inotropes remain a feasible method of managing SCAI stage B and C cardiogenic shock.
- 1 January 2021
- Published by SAGE Publications in Clinical Medicine Insights: Cardiology
- Vol. 15
Open AccessPredictors of In-hospital Mortality in Cardiogenic Shock Patients on Vasoactive or Inotropic Support
Though controversial, the short-duration in-patient use of inotropes in cardiogenic shock (CS) remain an ACC/AHA Class IIa indication, and are frequently used in the initial treatment of CS. We evaluated in-patient mortality and effect on mortality risk of commonly used vasoactive inotropic medications for the medical management of SCAI stage B and C cardiogenic shock patients in a tertiary care cardiac care unit: dobutamine, dopamine, milrinone, and norepinephrine. We retrospectively evaluated 342 patients who received dobutamine, milrinone, dopamine, norepinephrine or a combination of these medications for SCAI stage B and C cardiogenic shock. Cox proportional hazards were used to form longitudinal mortality predictions. Overall in-patient mortality was 18%. Each 1 µg/kg/minute increase in dobutamine independently corresponded to a 15% increase in risk of mortality. High dose dobutamine >3 µg/kg/minute is associated with 3-fold increased risk compared to ⩽3 µg/kg/minute (P < .001). Use of milrinone, norepinephrine, and dopamine were not independently associated with mortality. We demonstrate that the overall in-hospital mortality of SCAI stage B and C cardiogenic shock patients medically managed on inotropes was not in excess of prior studies. Dobutamine was independently associated with mortality, while other vasoactive inotropic medications were not. Inotropes remain a feasible method of managing SCAI stage B and C cardiogenic shock.